Page 161 - Binder2

antigens to antigen-presenting cells without danger
signals.

The result? A targeted induction of regulatory T cells,
specific to the antigen being delivered—reprogramming the
immune response from the inside out.

How It Works: The COUR Platform in Practice

At the core of COUR’s technology is a biodegradable
nanoparticle, engineered to encapsulate both a disease-
relevant antigen and immunomodulatory cues. Once
administered, the particle is taken up by liver-resident
antigen-presenting cells, which are predisposed to
promote tolerance rather than activation.

This is key: the liver, like the gut, is a site of natural
immune quiescence. The antigen is presented in a context
that suppresses inflammation and drives the expansion of
antigen-specific regulatory T cells (Tregs). These Tregs
then suppress the pathological immune response wherever
it occurs—in the pancreas (type 1 diabetes), in the gut
(celiac), or elsewhere.

It’s not immune evasion.
It’s immune instruction—and it’s built from first
principles to avoid the cascade of events that lead to
tolerization failure in traditional biologics.

159